Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 21 of 25 for:    "Lichen Sclerosus"

Methylene Blue Injection for Nonneoplastic Epithelial Disorders of Vulva (NNEDsMB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03200808
Recruitment Status : Active, not recruiting
First Posted : June 27, 2017
Last Update Posted : April 3, 2018
Sponsor:
Information provided by (Responsible Party):
Maternal and Child Health Hospital of Hubei Province

Brief Summary:

The aim of this study is to demonstrate the safety and effectiveness of mixed methylene blue compound Injection for the treatment of nonneoplastic epithelial disorders(NNEDS) of vulva.

NNEDS of skin and mucosa of vulva refer to a group of chronic diseases including squamous hyperplasia and lichen sclerosus, which mainly cause vulvar itching and hypopigmentation. Usually the itching is severe may influence social activities and sleep. In addition, NNEDS cause scarring of the vulva which may cause significant sexual dysfunction or pain. The reasons for NNEDs are not clear and the methods of treatment are diverse. The current treatments are primarily local drug (e.g. steroid, calcineurin inhibitors, immunosuppressive agents ), surgical treatments, laser or photodynamic therapy, and the "gold standard" treatment for lichen sclerosus is potent steroids creams. However, all the treatments are not good enough, and the diseases often recur and severely affect women's quality of life. So the investigators reviewed plenty of literatures, and found some authors used single intradermal 1% methylene blue injection for intractable idiopathic pruritus ani and the effect was good. As a preliminary experiment, the investigators used intradermal mixed methylene blue compound injection for a NNEDs patient in the year of 2012, the itching of the patient stopped immediately and the color of the vulva recovered 6 months later. The patient keeps healthy till now. And from then on, the investigators designed this study and to verify the effect and complications of intradermal mixed methylene blue compound injection for the treatment of NNEDS. So far, there is no similar study reported internationally.


Condition or disease Intervention/treatment Phase
Nonneoplastic Epithelial Disorders of Vulva Drug: mixed methylene blue compound injection Phase 1

Detailed Description:

Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.

In this study,the investigators used methylene blue compound injection intradermally to treat NNEDs patients. Patients with a diagnosis of biopsy proven NNEDs from Maternal and Child Health Hospital of Hubei Province (China) between October 2013 to October 2016 were recruited. Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department. Ages, itching scores, percentage of hypopigmented skin, and recurrences were recorded through inquiry and physical examination before and after treatment. Side effects (such as edema, fever and vulva pain) were also recorded. All women were followed up 1, 3, 6, 12 months after treatment, which included inquiry and physical examination.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 118 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Pations with nonneoplastic epithelial disorders(NNEDS) of vulva.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy of Mixed Methylene Blue Compound Injection for the Treatment of Nonneoplastic Epithelial Disorders of Vulva.
Study Start Date : October 2013
Actual Primary Completion Date : October 2016
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: treatment group

Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.

Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department.

Drug: mixed methylene blue compound injection
Every patient received intradermal mixed methylene blue compound injection twice.




Primary Outcome Measures :
  1. itching scores [ Time Frame: 1 years ]
    The patients rate the itching on a visual analogue scale (VAS) before and after the treatment. A VAS is a 100-mm long horizontal line with verbal descriptors at each end to express the extremes of the itching feeling. The most severe itching equals to score 10, and no itching equals to score 0. Patients marked the point on the line that best corresponded to their itching severity.


Secondary Outcome Measures :
  1. percentage of hypopigmented skin [ Time Frame: 1 years ]
    Doctors rate the hypopigmented skin on a vulva surface area scale (VSAS) before and after treatment through colposcopy. The vulva area is divided into six regions as labia majora, labia minora, interlabial sulci, clitoris and clitoral hood, perineum, and perianal area. The investigators estimated that the area percentage of labia majora, labia minora, interlabial sulci, clitoris and clitoral hood, perineum, and perianal area was 48%, 24%, 4%, 4%, 10% and 10% differently. Among the six regions, interlabial sulci, clitoris and clitoral hood, perineum, and perianal area could be divided into four equal proportions at most when the area percentage was calculated. And each side of labia majora and labia minora could be divided into four equal proportions at most. If all the vulva area is involved, the VSAS score is 100%, and if no area of vulva is involed, the VSAS score is 0%.


Other Outcome Measures:
  1. pathology changes [ Time Frame: 1 years ]
    changes of nonneoplastic epithelial disorders from biopsy pathology



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with clinically and biopsy confirmed non-neoplasia epithelial disorders of skin and mucosa of vulva.
  • Patient must have a score of 5 or greater in the itching score table before treatment and the itching must last at least 6 months.

Exclusion Criteria:

  • Patients with vulvovaginal or other gynecological trauma, acute inflammatory diseases and other acute illness
  • Patients have been treated with any kind of topical therapy at the vulva within 12 weeks prior to participation in the study
  • Patients with other serious diseases (e.g. liver or kidney diseases) that need immediate treatment
  • Patients with atypical vulvar hyperplasia or vulvar cancer confirmed by biopsy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03200808


Sponsors and Collaborators
Maternal and Child Health Hospital of Hubei Province
Investigators
Layout table for investigator information
Study Director: Han Gao, bachelor Maternal and Child health Hospital of Hubei Province,Wuhan,China
Study Chair: Xufeng Wu, PH.D Maternal and Child health Hospital of Hubei Province,Wuhan,China
Principal Investigator: Yanli Li, Master Maternal and Child health Hospital of Hubei Province,Wuhan,China

Publications:
Layout table for additonal information
Responsible Party: Maternal and Child Health Hospital of Hubei Province
ClinicalTrials.gov Identifier: NCT03200808     History of Changes
Other Study ID Numbers: NNEDs
First Posted: June 27, 2017    Key Record Dates
Last Update Posted: April 3, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Maternal and Child Health Hospital of Hubei Province:
Nonneoplastic Epithelial Disorders
methylene blue
treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Vulvar Diseases
Disease
Pathologic Processes
Genital Diseases, Female
Methylene Blue
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action